Polycystic liver and kidney disease: Post-transplant kidney function in patients receiving pre-emptive kidney transplantation

Transplant International

Volumn 21, Issue 3, 2008, Pages 263-267

  Martin, Adrian P ^a   Bartels, Michael ^a   Kiehle, Adrien ^a   Hauss, Johann ^a   Fangmann, Josef ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Polycystic liver and kidney disease; Post transplant kidney function; Pre emptive kidney transplantation; Tc99m MAG3 scintigraphy

Indexed keywords

CREATININE; MERTIATIDE TC 99M;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HUMAN; KIDNEY DISEASE; KIDNEY EXAMINATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

CADAVER; CREATININE; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVER DISEASES; LIVER TRANSPLANTATION; POLYCYSTIC KIDNEY DISEASES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 38849116980     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00601.x     Document Type: Article

References (26)

1. Gigot JF, Jadoul P, Que F, et al. Adult polycystic liver disease, is fenestration the most adequate operation for long-term management? Ann Surg 1997 3 : 286.
2. Madariaga JR, Iwatsuki A, Starzl TE, Todo S, Selby R, Zetti G. Hepatic resection for cystic lesions of the liver. Ann Surg 1993 5 : 610.
3. Newman KD, Torres VE, Rakela J, Nagorney DM. Treatment of highly symptomatic polycystic liver disease. Ann Surg 1990 212 : 30.
4. Turnage RH, Eckhauser FE, Knol JA, Thompson NW. Therapeutic dilemmas in patients with symptomatic polycystic liver disease. Am Surg 1988 4 : 365.
5. Soravia C, Mentha G, Giostra E, Morel P, Rohner A. Surgery for adult polycystic liver disease. Surgery 1995 117 : 272.
6. Ammori BJ, Jenkins BL, Lim PC, et al. Surgical strategy for cystic diseases of the liver in a western hepatobiliary center. World J Surg 2002 26 : 462.
7. Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium- 99m MAG3 as a hippuran replacement. J Nucl Med 1986 27 : 111.
8. Taylor A Jr., Eshima D, Fritzberg AR, Christian PE, Kasina S. Comparison of iodine-131 OIH and technetium- 99m MAG3 renal imaging in volunteers. J Nucl Med 1986 27 : 795.
9. Eshima D, Taylor A Jr. Technetium-99m mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent. Semin Nucl Med 1992 22 : 61.
10. Esteves FP, Halkar RK, Issa MM, Grant S, Taylor A. Comparison of camera-based 99mTc-MAG3 and 24-hour creatinine clearances for evaluation of kidney function. AmJRadiology 2006 187 : W316.
11. Taylor A, Manatunga A, Morton K, et al. Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance. Radiology 1997 204 : 47.
12. Lerut J, Ciccarelli O, Rutgers M, et al. Liver transplantation with preservation of the inferior vena cava in case of symptomatic adult polycystic disease. Transpl Int 2005 18 : 513.
13. Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995 59 : 361.
14. Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004 10 : 301.
15. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001 72 : 1934.
16. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002 8 : 91 Review).
17. Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl 2002 8 : 193 Review).
18. Ueno T, Barri YM, Netto GJ, et al. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. Transplantation 2006 82 : 501.
19. Pirenne J, Aerts R, Yoong K, et al. Liver transplantation for polycystic liver disease. Liver Transpl 2001 7 : 238.
20. Genzini T, Marchini G, Chang A, et al. Rangel influence of pancreas transplantation alone on native renal function. Transplant Proc 2000 38 : 1939.
21. Mazur MJ, Rea DJ, Griffin MD, et al. Decline in native renal function early after bladder-drained pancreas transplantation alone. Transplantation 2004 77 : 844.
22. Piccoli GB, Mezza E, Picciotto G, et al. The grafted kidney takes over: disappearance of the nephrotic syndrome after preemptive pancreas-kidney and kidney transplantation in diabetic nephropathy. Transplantation 2004 78 : 627.
23. Sanchez EQ, Martin AP, Ikegami T, et al. Sirolimus conversion after liver transplant: improvement in measured glomerular filtration rate after two years. Transplant Proc 2005 37 : 4416.
24. Mostov KE. mTOR is out of control in polycystic kidney disease. Proc Natl Acad Sci 2006 103 : 5247.
25. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006 21 : 598.
26. Shillingford JM, Murcia NS, Larson C, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci 2006 103 : 5466.